Marks Gilbert Lynn, a director at AN2 Therapeutics, Inc., has acquired an additional 2,283 shares of the company, as reported in a recent SEC filing. This acquisition brings his total ownership to 84,156 shares. The transaction took place on October 12, 2026, and was filed with the SEC on October 13, 2026.
This acquisition is significant as it underscores Lynn's ongoing commitment to AN2 Therapeutics, a company engaged in the pharmaceutical preparations sector. The filing indicates that the shares were issued in lieu of cash compensation under the company's non-employee director compensation policy, with all shares vesting immediately.
AN2 Therapeutics, Inc. is classified under the SIC code for Pharmaceutical Preparations, which reflects its focus on developing innovative therapies. The company is incorporated in Delaware and has its business operations based in Menlo Park, California.
According to the filing, the shares were acquired without any cost per share, indicating that this transaction is part of Lynn's compensation as a director. His role as a director positions him to influence the company's strategic decisions and direction.
The filing does not specify what actions may follow this acquisition, but it certainly reflects Lynn's confidence in the company's future prospects. This move could potentially impact investor sentiment towards AN2 Therapeutics as it signals a strong belief in the company's mission and objectives.
As the pharmaceutical industry continues to evolve, the actions of directors like Lynn may play a crucial role in shaping the company's trajectory and ensuring its competitive edge in the market.